Neoadjuvant letrozole plus palbociclib in patients (pts) with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) with baseline Ki67 >= 20% and an Oncotype DX Breast Recurrence Score (R) result (RS) >= 18: DxCARTES